Signos LegitScript and Accreditation Status: Is Signos Legit?

What Is LegitScript Certification and Does Signos Have It?

LegitScript is an independent third-party certification body that reviews online healthcare merchants, pharmacies, and health platforms against standards covering legal compliance, transparent business practices, and patient safety. Google, Meta, and many payment processors require LegitScript certification before allowing health-related advertising. As of January 2025, Signos does not appear in the LegitScript certified merchant database.

What LegitScript Certification Actually Means

LegitScript's certification process evaluates whether a company complies with applicable laws and regulations, maintains honest marketing claims, and protects consumer data. According to LegitScript's own published standards, certified merchants must demonstrate "compliance with applicable laws and regulations in the jurisdictions where they operate" and submit to ongoing monitoring. A missing certification does not automatically mean a company is fraudulent, but it does mean the platform has not been independently vetted by this particular compliance layer.

For consumers comparing telehealth weight-loss platforms, LegitScript certification has become a practical benchmark. Competitors such as Ro, Hims, and Noom have pursued or obtained LegitScript verification to qualify for broad digital advertising. Signos has not disclosed publicly why it has not sought or obtained this certification.

What This Means for Signos Consumers

The absence of LegitScript certification does not constitute a regulatory violation. Signos is not a pharmacy, so it is not subject to the LegitScript pharmacy certification pathway specifically. Still, the gap matters for two reasons. First, it removes a layer of independent compliance monitoring. Second, it limits Signos's ability to advertise across major digital platforms without workarounds, which may explain the company's heavy reliance on influencer marketing and affiliate programs.

Consumers should verify independently that any health platform they use operates with appropriate state business registrations and complies with FTC advertising guidelines (FTC health claims guidance).

FDA Status of the Devices Signos Uses

Signos does not manufacture its own continuous glucose monitor. The platform ships the Dexcom G6 or Dexcom G7 sensor to subscribers.

Dexcom's FDA Clearance

The Dexcom G6 received FDA clearance as a Class II medical device under 510(k) number K182006. The Dexcom G7 received its own FDA clearance in 2022. The FDA's device classification for continuous glucose monitors categorizes them under product code QMT for integrated CGMs. Both devices are cleared for use in diabetes management and are approved for adjunctive or replacement use in place of fingerstick testing.

Neither the G6 nor the G7 holds an FDA indication specifically for weight management in non-diabetic individuals. Signos's use of these sensors for metabolic weight coaching in euglycemic adults represents an off-label application of a cleared device.

The Off-Label Use Question

Off-label use of medical devices is legal and common in clinical practice. Physicians routinely use cleared devices outside their labeled indications when evidence supports the practice. However, Signos markets CGM use directly to consumers without a physician intermediary reviewing whether the sensor is appropriate for each individual. The FDA does not currently regulate the software coaching layer of the Signos app as a separate device, though the agency's Software as a Medical Device (SaMD) framework could apply to algorithmic recommendations that influence health decisions.

Signos's BBB Profile and Consumer Complaint Record

Signos is not BBB-accredited as of January 2025. The Better Business Bureau profile for Signos shows a pattern of complaints centered on three recurring categories: billing and subscription cancellation difficulties, unmet expectations regarding weight-loss outcomes, and customer service responsiveness.

Common Complaint Themes

Reviewers on the BBB platform and on Trustpilot describe scenarios where cancellation requests were not processed before the next billing cycle, leading to unexpected charges. Several complaints reference difficulty reaching live support. One BBB complaint, representative of the pattern, describes a consumer who reported: "I cancelled within the stated window and was still charged for another month. It took four emails and three weeks to receive a partial refund."

These types of billing complaints are not unique to Signos and are common across the direct-to-consumer health subscription category. Still, their volume and recurrence signal a customer experience gap that prospective subscribers should weigh.

Independent Review Aggregators

On the App Store, Signos holds approximately a 4.7/5 rating from a relatively small sample of reviews, skewed toward highly engaged users who find value in the glucose feedback loop. Third-party review aggregators that sample a broader population tend to reflect more mixed sentiment, with recurring friction around cost-to-benefit ratio. The subscription price of approximately $399 per month is a consistent point of dissatisfaction for members who did not lose significant weight.

A useful framework for evaluating any CGM-based weight program is to separate three distinct questions: (1) Is the underlying device safe and accurately calibrated? (2) Does the coaching software generate clinically meaningful behavioral change? (3) Does the business model protect consumers from predatory billing? For Signos, the answer to the first question is clearly yes given Dexcom's regulatory standing. The second and third questions carry more uncertainty.

Clinical Evidence for CGM-Guided Weight Loss in Non-Diabetics

This is the most consequential question for anyone considering Signos. The platform's entire value proposition depends on whether real-time glucose feedback changes eating behavior enough to produce meaningful weight reduction in people without diabetes.

What the Research Actually Shows

A 2023 randomized controlled trial published in JAMA Internal Medicine (N=153 adults with overweight or obesity, no diabetes) tested CGM-guided dietary coaching versus standard dietary coaching over 12 weeks. The CGM group lost a mean of 2.0 kg compared to 1.6 kg in the control group, a difference that did not reach statistical significance (P<0.24) [1]. The authors concluded that CGM feedback alone, without pharmacotherapy, produced "no significant additional weight loss" beyond standard dietary advice in this population.

A separate 2022 pilot study in Obesity Science and Practice (N=23) found that wearing a CGM for four weeks increased dietary awareness in non-diabetic adults but produced average weight loss of only 0.8 kg, a figure the investigators described as modest and insufficient for clinical benchmarking [2].

For comparison, the GLP-1 receptor agonist semaglutide 2.4 mg (Wegovy) produced 14.9% mean weight loss at 68 weeks versus 2.4% in the placebo group in the STEP-1 trial (N=1,961) [3]. CGM-only programs operate in a fundamentally different efficacy range.

What Signos's Own Research Claims

Signos has published internal observational data on its website suggesting that members who follow its glucose-stability protocol lose more weight than those who do not. This data has not been peer-reviewed or published in an indexed journal, which limits its evidentiary weight. The company cites a small internal cohort of members rather than a controlled external study. Signos has also referenced research by Stanford metabolic biologist Dr. Michael Snyder, whose work on continuous glucose monitoring in non-diabetic individuals explores glucose variability as a marker of metabolic health [4], though Dr. Snyder's published research does not evaluate the Signos platform directly and does not establish a causal weight-loss effect.

Where CGM Genuinely Helps

Real-time glucose feedback does appear to help some non-diabetic users identify foods that cause large postprandial spikes. A 2022 study in Cell Metabolism (N=1,002) showed that individuals exhibit highly personalized glycemic responses to identical foods, suggesting that personalized dietary guidance based on individual glucose patterns has biological plausibility [5]. The gap is between biological plausibility and demonstrated clinical weight loss outcomes.

Signos's Subscription Model: What You Are Actually Buying

Signos charges approximately $399 per month for a plan that includes two Dexcom sensors (each lasting 10 days, for approximately 20 days of coverage per month), access to the Signos app, and automated coaching prompts based on glucose readings.

Pricing Transparency

Longer commitment plans reduce the monthly cost modestly. An annual subscription lowers the per-month price to approximately $299. The Dexcom sensors themselves retail separately for approximately $120 to $140 per sensor for cash-pay consumers, meaning the Signos markup covers app access and shipping logistics. Health insurance does not cover CGMs for weight management in non-diabetic individuals under current coverage standards; the American Diabetes Association's 2024 Standards of Care do not include CGM recommendations for metabolically healthy adults seeking weight loss [6].

Cancellation Policy Concerns

Based on publicly available BBB complaints and App Store reviews, cancelling a Signos subscription requires contacting support directly rather than using a self-service portal. This friction-based cancellation model is legal but has generated a disproportionate share of the brand's negative consumer feedback. Prospective members should document their cancellation requests with timestamps and keep email confirmation records.

Medical Oversight and Prescriber Involvement

Signos is not a telehealth prescriber. The platform does not connect members with licensed physicians for GLP-1 prescriptions, metabolic blood panels, or individualized medical supervision. A user signs up, receives a CGM kit, and interacts primarily with an algorithm-driven app.

Comparison to Physician-Supervised Programs

Telehealth platforms that combine CGM with GLP-1 therapy, such as Found or Sequence (now part of WeightWatchers+), offer physician consultations as part of their intake process. Signos does not. For individuals with a BMI <30 who are seeking modest improvements in metabolic awareness rather than pharmacological treatment, the Signos model may be appropriate. For individuals with a BMI >30, cardiovascular risk factors, or prediabetes, a physician-supervised program with access to evidence-based pharmacotherapy provides substantially greater clinical benefit per dollar spent.

The Endocrine Society's 2023 obesity management guidelines state that lifestyle intervention alone achieves clinically meaningful weight loss (defined as 5% or more of body weight) in only 30 to 40% of participants over 12 months, and that adjunctive pharmacotherapy significantly improves those rates [7].

Signos and FTC Marketing Standards

Signos markets heavily through social media influencers and affiliate publishers, many of whom present the product without disclosing financial relationships. The FTC's revised Endorsement Guides, updated in 2023, require clear and conspicuous disclosure of material connections between endorsers and brands. Consumers who encounter Signos promotions through fitness influencers or health bloggers should check whether posts carry #ad or #sponsored disclosures.

The company's own website marketing uses before-and-after testimonials. The FTC has specific guidelines requiring that testimonials reflect typical results rather than exceptional outcomes. Signos's testimonials have not, to date, been the subject of a public FTC enforcement action, but the marketing patterns warrant consumer-level scrutiny.

Who Should and Should Not Consider Signos

Not everyone is a poor candidate for CGM-based metabolic programs. Some individuals gain genuine value from the biofeedback.

Profiles That May Benefit

Adults with prediabetes (fasting glucose 100 to 125 mg/dL) may find CGM data actionable because their glucose responses to carbohydrates are more variable and correctable through diet. Individuals who have failed generic dietary advice and want objective food-response data as a starting point could find the first one to three months of Signos useful for identifying personal glycemic patterns. Competitive athletes who want to optimize fueling and recovery timing represent another niche where glucose monitoring provides real signal.

Profiles That Are Unlikely to Benefit

Adults with obesity requiring more than 5% weight loss are unlikely to achieve clinically meaningful results through CGM feedback alone based on current trial data. Individuals who have not first addressed basic dietary habits, sleep, and activity levels are better served by behavioral interventions with established evidence bases before adding a $399 monthly hardware subscription. Anyone seeking the weight-loss magnitude achievable with GLP-1 therapy should consult a physician rather than a CGM app.

Summary of Accreditation, Safety, and Legitimacy Factors

Signos occupies a middle ground that is common in the digital health space. The company operates legally, uses FDA-cleared hardware, and provides a real product that some users find valuable. At the same time, it lacks independent accreditation, carries a notable consumer complaint volume, makes marketing claims that outpace the available clinical trial evidence, and operates without meaningful physician oversight.

The most precise statement available: Signos is not a scam in the sense of delivering nothing, but its clinical effectiveness for weight loss in the general non-diabetic population is not supported by large, independent randomized controlled trials, and its consumer experience around billing and cancellation has generated persistent complaints that the company has not fully resolved.

Prospective subscribers should enter with realistic expectations, understand that the monthly cost is entirely out-of-pocket, and document any cancellation decision immediately to avoid unauthorized renewal charges.